![]() | |
Clinical data | |
---|---|
Trade names | Eovist |
Other names | Gadoxetate disodium ( USAN US) |
AHFS/ Drugs.com | International Drug Names |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C23H30GdN3O11 |
Molar mass | 681.75 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Gadoxetic acid is a gadolinium-based MRI contrast agent. [3] Its salt, gadoxetate disodium, is marketed as Primovist in Europe and Eovist in the United States by Bayer HealthCare Pharmaceuticals. [1] [4]
It is used to increase the T1 signal intensity while imaging the liver lesions such as benign cysts, hemangioma, and liver cancer. It is excreted into bile by active secretion. [5]
In those with end-stage renal failure, the clearance rate is only 17% with terminal half-life of 12 times longer than those with normal renal function. [5]